Abstract
476 Background: In the CRYSTAL study cetuximab (cet) added to first-line chemotherapy (CT) significantly improved tumor response compared with CT alone in patients (pts) with KRAS wild-type (wt) mCRC, confirming existing data in this setting. Response to CT has been reported to lead to a corresponding increase in QoL, and QoL scores to predict overall survival in mCRC. In this exploratory analysis tumor response and QoL was investigated in pts from the CRYSTAL study. Methods: Pts were classified as responders (Rs) or nonresponders (NRs) according to best overall response. QoL was assessed using single-item symptoms questions from the EORTC QLQ-C30 (q8-10, q12-18). Pts at baseline were considered symptomatic if they answered “quite a bit” or “very much” and asymptomatic if they answered “not at all” or “a little” to either one of the symptoms questions. Analysis was performed in all treatment groups (gps) on the change in symptoms in pts considered symptomatic or asymptomatic at baseline. Results: 471 of 627 KRAS wt pts assessed for QoL had baseline data showing they were symptomatic or asymptomatic. In pts asymptomatic at baseline (n=278) there were more Rs (58%) than NRs (42%). In pts symptomatic at baseline (n=193), there were less Rs (40%) than NRs (60%). At week 8 in all treatment gps, in pts symptomatic at baseline more Rs than NRs became asymptomatic (Table). In pts asymptomatic at baseline, in the CT + cet gp at week 8, 61% of Rs remained asymptomatic compared with 50% of NRs. Data from week 16 and 24 also showed trends in favor of Rs in symptomatic or asymptomatic pts at baseline and will be presented. Conclusions: Rs who are symptomatic at baseline experience higher symptom relief than NRs. Furthermore Rs who are asymptomatic at baseline are more likely to remain asymptomatic post baseline than NRs. These findings are independent of treatment. [Table: see text] [Table: see text]
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
